Version May 2024
Atopic dermatitis: Topical: Apply a thin film to affected area(s) 2 times daily; consider reducing to once daily when clinical response is achieved.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
(For additional information see "Crisaborole: Pediatric drug information")
Atopic dermatitis, mild to moderate: Infants ≥3 months, Children, and Adolescents: Topical: Apply a thin film to affected area(s) 2 times daily; consider reducing to once daily when clinical response is achieved.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.
1% to 10%: Local: Application-site pain (4%; including application-site burning and stinging of the skin)
<1%: Dermatologic: Urticaria
Frequency not defined: Hypersensitivity: Hypersensitivity reaction
Postmarketing: Dermatologic: Allergic contact dermatitis
Hypersensitivity to crisaborole or any component of the formulation
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions have been reported, including contact urticaria. Severe pruritus, swelling, or erythema (at the application site or at a distant site) may be indicative of hypersensitivity. Discontinue immediately for signs of hypersensitivity.
Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Ointment, External:
Eucrisa: 2% (60 g, 100 g) [contains edetate (edta) calcium disodium, propylene glycol]
No
Ointment (Eucrisa External)
2% (per gram): $15.26
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Ointment, External:
Eucrisa: 2% (30 g, 60 g, 100 g) [contains edetate (edta) calcium disodium, propylene glycol]
For topical use only; not for ophthalmic, oral, or intravaginal use.
Topical: For topical use only; not for ophthalmic, oral, or intravaginal use. Wash hands before and after use; apply in thin layer to affected area.
Atopic dermatitis: Topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients ≥3 months of age.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Riociguat: Crisaborole may enhance the hypotensive effect of Riociguat. Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension. Risk C: Monitor therapy
Adverse effects were not observed in animal reproduction studies, except with high oral doses which also produced maternal toxicity.
It is not known if crisaborole is excreted in breast milk; however, it is absorbed systemically following topical application. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.
Signs of hypersensitivity
Inhibits phosphodiesterase 4 (PDE-4) and results in increased intracellular cyclic adenosine monophosphate (cAMP) levels.
Protein binding: 97%
Metabolism: Hepatic to 2 inactive metabolites via hydrolysis and oxidation
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
